We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-12.75%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$189M
AUM Growth
-$23.4M
Cap. Flow
+$27.5M
Cap. Flow %
14.56%
Top 10 Hldgs %
53.8%
Holding
36
New
10
Increased
6
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
AKBA icon
Akebia Therapeutics
AKBA
+$10.2M
2
PCVX icon
Vaxcyte
PCVX
+$9.24M
3
IMVT icon
Immunovant
IMVT
+$7.84M
4
ASND icon
Ascendis Pharma A/S
ASND
+$7.14M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$6.45M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$8.35M
2
KALV
KalVista Pharmaceuticals
KALV
+$7.89M
3
JSPR icon
Jasper Therapeutics
JSPR
+$6.89M
4
ORKA
Oruka Therapeutics
ORKA
+$4.44M
5
DVAX
Dynavax Technologies
DVAX
+$3.49M

Sector Composition

Rank Sector Weight
1 Healthcare 97.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTX icon
26
Context Therapeutics
CNTX
$55.1M
$2.87M 1.52%
4,683,711
– –
RZLT icon
27
Rezolute
RZLT
$454M
$2.42M 1.28%
833,042
+211,148
+34% +$920K
CNTA
28
DELISTED
Centessa Pharmaceuticals
CNTA
$2.15M 1.14%
+149,702
New +$2.45M
VYGR icon
29
Voyager Therapeutics
VYGR
$183M
$2.12M 1.12%
626,275
-200,476
-24% -$936K
PMN icon
30
ProMIS Neurosciences
PMN
$123M
$1.84M 0.97%
105,805
– –
UPB
31
Upstream Bio Inc
UPB
$343M
$1.84M 0.97%
300,000
– –
PLRX icon
32
Pliant Therapeutics
PLRX
$64.4M
$1.15M 0.61%
850,000
-205,000
-19% -$1.24M
JSPR icon
33
Jasper Therapeutics
JSPR
$21M
– –
-322,380
Closed -$6.89M
OPTN
34
DELISTED
OptiNose
OPTN
– –
-370,269
Closed -$2.47M
URGN icon
35
UroGen Pharma
URGN
$1.86B
– –
-187,843
Closed -$2M
ORKA
36
Oruka Therapeutics
ORKA
$5.82B
– –
-228,803
Closed -$4.44M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Great Point Partners held 36 positions worth $189M, down 11% from $212M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Great Point Partners deployed $27.5M of net new capital in Q1 2025, opening 10 new positions and adding to 6 existing holdings. Its largest new stake was Akebia Therapeutics: 4,973,840 shares worth $9.55M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $8.35M trimmed.

  • Great Point Partners's largest Q1 2025 buy was Akebia Therapeutics: 4,973,840 shares worth $9.55M.
  • Great Point Partners added most to Merus in Q1 2025, an estimated $3.45M increase.
  • Great Point Partners's biggest Q1 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $8.35M.
  • Great Point Partners fully exited Jasper Therapeutics in Q1 2025, selling an estimated $6.89M.
  • Great Point Partners's ten largest holdings make up 54% of its $189M portfolio in Q1 2025.
  • Great Point Partners opened 10 new positions and closed 4 in Q1 2025.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $189M.

Based on Great Point Partners's 13F filing for Q1 2025, filed 15 May 2025.